ea0020p323 | Clinical case reports and clinical reports | ECE2009
, Kostoglou-Athanassiou Ifigenia
, Goudouvas Anastasios
, Thomas Dimitrios
, Tertipi Athanasia
, Ziras Nikolaos
Although the prognosis of thyroid cancer is in general quite favorable when standard management paradigms are applied, some patients do much less well. Radioactive iodine refractory, recurrent or metastatic disease is prognostically more worrisome. Sorafenib, a multitargeted small molecule kinase inhibitor, including the VEGF receptor and BRAF kinase, has been evaluated in patients with thyroid cancer. The aim of the study was to present a case of metastatic thyroid cancer and...